Invivyd, Inc. is a microcap biotech company focusing on antibody-based treatments for infectious diseases like COVID-19.

Invivyd has teamed up with professional football coach Jim Harbaugh to tackle COVID-19 complacency. The biotech, which has ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

周一，在Invivyd Inc. (NASDAQ: IVVD )取得一系列积极进展后，H.C. Wainwright重申了其买入评级和10.00美元的目标价。该公司目前股价为1.06美元，市值1.2679亿美元，过去一周股价涨幅达156%。在评估了多个关键因素（包括最新财务业绩、管理层会议和临床数据）后，该机构分析师对Invivyd表示出更大的信心。

Invivyd, Inc. (NASDAQ:IVVD – Get Free Report) was the recipient of unusually large options trading on Thursday. Traders ...

Biotechnology is a high-risk, high-reward landscape where innovation determines success. Yet, occasionally, a small player ...

PEMGARDA™ (pemivibart) net product revenue of $13.8 million, 48% growth over Q3 2024 net product revenue of $9.3 ...

Invivyd data shows strong potency and prolonged antibody levels in trials. Q4 Pemgarda revenue rose 48% to $13.8 million.

Teaming up to raise awareness of the continuing toll of COVID-19 in America, an ongoing mass disabling event causing an American death ...

WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced ...

在其他近期新闻中，Invivyd, Inc.宣布了一系列重大进展。这家生物科技公司已申请FDA批准使用其COVID-19治疗药物pemivibart用于免疫功能低下的患者。该治疗方法显示出良好的风险收益比，并有潜力在单次给药后提供数月的显著抗病毒活性。Invivyd第三季度财务业绩显示稳定增长，净产品收入为930万美元，公司通过战略重组计划在2025年6月前实现盈利。